Trial
NCT04605094
Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
IQVIA Pty Ltd
Condition
Atopic Dermatitis
Intervention
Benralizumab
Why stopped
The study did not meet the primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-31